Ernexa Therapeutics (ERNAW) Other Non-Current Assets (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Other Non-Current Assets data on file, last reported at $110000.0 in Q1 2026.

• Quarterly Other Non-Current Assets fell 6.78% year-over-year to $110000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110000.0 (down 6.78% YoY) and the FY2025 annual result came in at $110000.0, down 6.78% from the prior year.
• Other Non-Current Assets steadied at $110000.0 in Q1 2026, from $110000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $4.1 million in Q4 2023 to a low of $63000.0 in Q1 2022.
• A 5-year average of $1.2 million and a median of $120000.0 in 2024 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 6400.0% — and 2025, when it plunged 97.14%.
• Tracing ERNAW's Other Non-Current Assets over 5 years: stood at $1.1 million in 2022, then surged by 261.55% to $4.1 million in 2023, then sank by 97.12% to $118000.0 in 2024, then slipped by 6.78% to $110000.0 in 2025, then changed by 0.0% to $110000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $110000.0 (Q1 2026), $110000.0 (Q4 2025), and $116000.0 (Q3 2025), per Business Quant data.